Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Response to Influenza Vaccine in Subjects With B-cell Malignancies Treated With Idelalisib

NCT03701438 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03701438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03701438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Response to Influenza Vaccine in Subjects With B-cell Malignancies Treated With Idelalisib
Lead sponsor
Gilead Sciences
Phase
Observational
Overall status
Terminated
Start date
October 23, 2018
Completion date
October 9, 2019
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies